Biotech market on the upswing: Cathie Wood is increasingly buying stocks - an overview of her biotech investments.

Biotech market on the upswing: Cathie Wood is increasingly buying stocks - an overview of her biotech investments.

According to a report by www.boerse-online.de,

Cathie Wood, the well-known investor, increased her investments in biotech companies in November. She bought shares of Intellia Therapeutics, Crispr Therapeutics, Recursion Pharmaceuticals and even Moderna for her ETFs. These investments could have a significant impact on the biotech market.

Intellia Therapeutics, a U.S. company focused on genome editing, has been targeted by Wood for multiple stock purchases. Other experts are also optimistic and see significant upside potential for the stock.

Crispr Therapeutics, which developed the genetic engineering “Crispr/Cas9,” also benefited from Cathie Wood's investments. The share gains since the beginning of the year as well as the experts' forecasts suggest considerable price potential here too.

The investments in Recursion Pharmaceuticals and Moderna show that larger, established companies are also in Cathie Wood's focus.

Cathie Wood's increased investments in the biotech industry could heat up the market through the end of the year and attract more investors to these companies.

Demand for shares of these companies could increase, which could cause prices to rise. However, such investments always involve a certain amount of risk. It remains to be seen what developments will be in the biotech market and in the financial industry as a whole.